VLTR-559

VLTR-559 is a long-acting, highly engineered anti-VEGF (vascular endothelial growth factor) biologic therapy in preclinical development for the treatment of wet age-related macular degeneration (wet AMD). Developed by Valitor, it leverages the company’s proprietary Multivalent Polymer (MVP) technology platform, which conjugates anti-VEGF antibody fragments to large molecular weight hyaluronic acid biopolymers. This design aims to significantly increase both potency and intravitreal half-life compared to current standard-of-care anti-VEGF therapies. Preclinical data indicate that VLTR-559 maintains high drug concentrations in ocular tissues and demonstrates a safety profile consistent with marketed anti-VEGF biologics. The therapy is intended to enable twice-yearly dosing—substantially reducing injection frequency from the current 8–12 week interval required by existing treatments—potentially improving patient outcomes and reducing clinical burden[1][3][5][6][9].